We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+2.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$833M
AUM Growth
-$400M
(-32%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-28.81%
Top 10 Holdings %
Top 10 Hldgs %
56.65%
Holding
156
New
48
Increased
29
Reduced
27
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$25M |
| 2 |
CELG
Celgene Corp
CELG
|
+$22.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$21.2M |
| 4 |
MacroGenics
MGNX
|
+$18.8M |
| 5 |
MannKind Corp
MNKD
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$144M |
| 2 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
+$69.5M |
| 3 |
Gilead Sciences
GILD
|
+$56.7M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
+$26.6M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.14% |
| 2 | Miscellaneous | 12.73% |
| 3 | Consumer Staples | 2.06% |
| 4 | Consumer Discretionary | 0.05% |
| 5 | Industrials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zimmer Biomet
ZBH
$18.8B
| $1.86M | 0.22% |
+20,600
| New | +$1.78M |
|
|
CLVS
52
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.84M | 0.22% |
30,585
-164,116
| -84% | -$8.93M |
|
|
IDIX
53
CALL
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $1.79M | 0.22% |
+300,000
| New | +$1.39M |
|
54
Lisata Therapeutics
LSTA
$13.9M
| $1.57M | 0.19% |
1,531
-680
| -31% | -$672K |
|
55
BioCryst Pharmaceuticals
BCRX
$2.09B
| $1.5M | 0.18% |
197,500
+6,912
| +4% | +$43.8K |
|
|
SNTS
56
DELISTED
SANTARUS INC
SNTS
| $1.45M | 0.17% |
45,400
-486,843
| -91% | -$13.7M |
|
|
SHPG
57
DELISTED
Shire pic
SHPG
| $1.41M | 0.17% |
+10,000
| New | +$1.31M |
|
|
ANTH
58
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $1.32M | 0.16% |
53,932
| – | – |
|
|
RPRX
59
DELISTED
Repros Therapeutics Inc.
RPRX
| $1.31M | 0.16% |
71,879
-1,409,854
| -95% | -$26.6M |
|
60
DexCom
DXCM
$32.6B
| $1.06M | 0.13% |
120,000
-170,200
| -59% | -$1.35M |
|
|
TBIO
61
DELISTED
TRANGSGENOMIC INC
TBIO
| $1M | 0.12% |
2,207,500
| – | – |
|
62
Curis
CRIS
$2.74M
| $987K | 0.12% |
+175
| New | +$1.2M |
|
|
VVUS
63
PUT
DELISTED
Vivus Inc
VVUS
| $908K | 0.11% |
10,000
-18,950
| -65% | -$1.83M |
|
|
CASC
64
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $880K | 0.11% |
83,333
+2,916
| +4% | +$32.6K |
|
65
MiMedx Group
MDXG
$689M
| $874K | 0.11% |
+100,000
| New | +$612K |
|
|
UPI
66
DELISTED
UROPLASTY INC-NEW
UPI
| $857K | 0.1% |
313,989
+10,000
| +3% | +$30.5K |
|
67
United Therapeutics
UTHR
$21.5B
| $792K | 0.1% |
+7,000
| New | +$631K |
|
|
SCAI
68
DELISTED
Surgical Care Affiliates, Inc.
SCAI
| $697K | 0.08% |
+20,000
| New | +$611K |
|
|
NSPH
69
DELISTED
NANOSPHERE INC. COM NEW
NSPH
| $676K | 0.08% |
14,750
-2,225
| -13% | -$93.2K |
|
|
HOLX
70
CALL
DELISTED
Hologic
HOLX
| $559K | 0.07% |
+25,000
| New | +$551K |
|
|
BLUE
71
DELISTED
bluebird bio
BLUE
| $420K | 0.05% |
+1,544
| New | +$431K |
|
|
DS
72
DELISTED
Drive Shack Inc.
DS
| $402K | 0.05% |
+77,400
| New | +$389K |
|
|
GNMX
73
DELISTED
Aevi Genomic Medicine Inc
GNMX
| $367K | 0.04% |
61,263
-88,737
| -59% | -$580K |
|
|
ATHN
74
CALL
DELISTED
Athenahealth, Inc.
ATHN
| $336K | 0.04% |
+2,500
| New | +$321K |
|
75
Microbot Medical
MBOT
$96.7M
| $334K | 0.04% |
168
+25
| +17% | +$52.9K |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q4 2013 Portfolio in Review
As of Q4 2013, Perceptive Advisors held 156 positions worth $833M, down 32% from $1.23B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Perceptive Advisors withdrew a net $240M in Q4 2013, closing 47 positions and reducing 27 holdings. Its most notable exit was ONYX PHARMACEUTICALS INC, an estimated $69.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Perceptive Advisors opened a new position in MacroGenics worth $19.7M.
- Perceptive Advisors's largest Q4 2013 buy was MacroGenics: 717,705 shares worth $19.7M.
- Perceptive Advisors added most to Vertex Pharmaceuticals in Q4 2013, an estimated $25M increase.
- Perceptive Advisors's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $144M.
- Perceptive Advisors fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $69.5M.
- Perceptive Advisors's ten largest holdings make up 57% of its $833M portfolio in Q4 2013.
- Perceptive Advisors opened 48 new positions and closed 47 in Q4 2013.
- Perceptive Advisors's portfolio value fell 32% quarter-over-quarter to $833M.
Based on Perceptive Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.